This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (4)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Pat Phillips

JAMA. 1999;282:1118-1119.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Vancouver, BC—The first major international study to assess factors that influence quality of life in patients with Parkinson disease (PD) has found that the most powerful impact comes from depression rather than from the severity of the disorder or adverse effects of medication.

"The key finding of the Global Parkinson Disease Survey (GPDS) is that depression has an overwhelming impact on quality of life, as measured by Beck's Depression Inventory [BDI]," said Tobias E. Eichhorn, MD, of Philipps University, Marburg, Germany, who analyzed the clinical implications of the study results. "It is the first step that will form the basis of intervention studies to determine how to treat different degrees of depression in these patients." Later he added that, since there have been no trials specifically involving antidepressant treatment of patients with PD, various classes of drugs should be studied to determine which will be of most . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Rehabilitation for Parkinson's disease: a systematic review of available evidence
Gage and Storey
Clin Rehabil 2004;18:463-482.
ABSTRACT